Published in the Scandinavian Journal of Gastroenterology, the study centers on the use of Bifidobacterium lactic HN019-a combination product of Danisco’s HOWARU Bifido strain and Fonterra’s DR10 strain.
A collaborative study between Danisco (Copenhagen) and Fonterra (Auckland, New Zealand) provides new support for digestive health probiotics and decreased colonic transit time.
Published in the Scandinavian Journal of Gastroenterology, the study centers on the use of Bifidobacterium lactic HN019-a combination product of Danisco’s HOWARU Bifido strain and Fonterra’s DR10 strain. Researchers assigned 100 patients to a high dose of the probiotic product, a low dose or placebo for 14 weeks. Colonic transit time of food was measured as an indication of any improvements in digestive health with either probiotic or placebo.
Results of the study indicated that colonic transit time was improved in a dose-dependent manner with the probiotic. Transit time decreased by an average 28 hours in the high-dose group and by an average 19 hours in the low-dose group. No reduction was observed in the placebo group and food consumption habits remained similar for all groups.
For more details, visit the study abstract at the link above.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.
New review paper highlights gut-brain benefits of novel herbal blend, Digexin
September 16th 2024NXT USA has announced the publication of a narrative review that offers an in-depth analysis of the efficacy and safety of its Digexin ingredient, which is a novel blend of Ashwagandha and okra extracts.